Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
TroFuse-019
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- NCT06312137 ↗
- Recruiting
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on TroFuse-019 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TroFuse-019 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Sacituzumab tirumotecan; Pembrolizumab; Cisplatin; Pemetrexed; Gemcitabine; Carboplatin; Paclitaxel; Rescue medication
- Arms
- Pembrolizumab + Sacituzumab tirumotecan · Experimental
- Pembrolizumab · Active comparator
- Enrollment
- 780 (estimated)
- Primary outcomes
- Disease-free survival (DFS) as assessed by Blinded Independent Central Review (BICR)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Apr 3, 2024
- Primary completion
- Feb 21, 2034 (estimated)
- Results posted
- No
- Registry record
- NCT06312137 · updated Oct 15, 2026